Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
Animals
Cytokines
/ metabolism
Disease Models, Animal
Dopamine
/ metabolism
Dopaminergic Neurons
/ metabolism
Humans
Inflammation
Male
Microglia
/ metabolism
Neurons
/ metabolism
Parkinson Disease
/ physiopathology
Phagocytosis
Phosphorylation
Rats
Rats, Sprague-Dawley
Recombinant Proteins
/ metabolism
Substantia Nigra
/ metabolism
alpha-Synuclein
/ metabolism
Parkinson disease
cognitive impairment
microglia
motor deficits
neurodegeneration
neuroinflammation
α-synuclein oligomers
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Nov 2020
12 Nov 2020
Historique:
received:
22
09
2020
revised:
04
11
2020
accepted:
09
11
2020
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
7
4
2021
Statut:
epublish
Résumé
The accumulation of aggregated α-synuclein (αSyn) is a hallmark of Parkinson's disease (PD). Current evidence indicates that small soluble αSyn oligomers (αSynOs) are the most toxic species among the forms of αSyn aggregates, and that size and topological structural properties are crucial factors for αSynOs-mediated toxicity, involving the interaction with either neurons or glial cells. We previously characterized a human αSynO (H-αSynO) with specific structural properties promoting toxicity against neuronal membranes. Here, we tested the neurotoxic potential of these H-αSynOs in vivo, in relation to the neuropathological and symptomatic features of PD. The H-αSynOs were unilaterally infused into the rat substantia nigra pars compacta (SNpc). Phosphorylated αSyn (p129-αSyn), reactive microglia, and cytokine levels were measured at progressive time points. Additionally, a phagocytosis assay in vitro was performed after microglia pre-exposure to αsynOs. Dopaminergic loss, motor, and cognitive performances were assessed. H-αSynOs triggered p129-αSyn deposition in SNpc neurons and microglia and spread to the striatum. Early and persistent neuroinflammatory responses were induced in the SNpc. In vitro, H-αSynOs inhibited the phagocytic function of microglia. H-αsynOs-infused rats displayed early mitochondrial loss and abnormalities in SNpc neurons, followed by a gradual nigrostriatal dopaminergic loss, associated with motor and cognitive impairment. The intracerebral inoculation of structurally characterized H-αSynOs provides a model of progressive PD neuropathology in rats, which will be helpful for testing neuroprotective therapies.
Identifiants
pubmed: 33198335
pii: ijms21228535
doi: 10.3390/ijms21228535
pmc: PMC7696693
pii:
doi:
Substances chimiques
Cytokines
0
Recombinant Proteins
0
SNCA protein, human
0
alpha-Synuclein
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/N000676/1
Pays : United Kingdom
Organisme : European Research Council
ID : 819644
Pays : International
Références
J Neurochem. 2009 Oct;111(1):192-203
pubmed: 19686384
J Neurochem. 2016 Oct;139 Suppl 1:131-155
pubmed: 27018978
Acta Neuropathol. 2018 Oct;136(4):621-639
pubmed: 30046897
Acta Neuropathol. 2018 Jan;135(1):65-83
pubmed: 29209768
J Neurosci Methods. 1991 Sep;39(2):153-61
pubmed: 1798345
Brain Behav Immun. 2018 Mar;69:591-602
pubmed: 29458199
Neurobiol Dis. 2017 Sep;105:84-98
pubmed: 28576704
Mov Disord. 2016 Oct;31(10):1535-1542
pubmed: 27548849
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E1994-2003
pubmed: 25855634
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9
pubmed: 21325059
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):897-909
pubmed: 20074453
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12479-84
pubmed: 22802614
Nat Commun. 2013;4:1562
pubmed: 23463005
Mov Disord. 2019 Nov;34(11):1699-1710
pubmed: 31449702
PLoS One. 2010 Oct 26;5(10):e13481
pubmed: 21048992
Exp Neurol. 2012 Oct;237(2):318-34
pubmed: 22750327
J Exp Med. 2016 Aug 22;213(9):1759-78
pubmed: 27503075
Neuron. 2018 Oct 10;100(1):75-90.e5
pubmed: 30308173
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Int J Neurosci. 2021 Aug;131(8):765-774
pubmed: 32441169
J Neuropathol Exp Neurol. 2008 Dec;67(12):1149-58
pubmed: 19018246
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8
pubmed: 12122208
Ann Neurol. 2014 Mar;75(3):351-62
pubmed: 24243558
ACS Chem Biol. 2019 Jun 21;14(6):1352-1362
pubmed: 31050886
Neurology. 2010 Nov 16;75(20):1766-72
pubmed: 20962290
Nat Commun. 2016 Sep 19;7:12563
pubmed: 27640673
Int Rev Cell Mol Biol. 2017;329:79-143
pubmed: 28109332
Eur Neuropsychopharmacol. 2010 Jan;20(1):25-36
pubmed: 19854030
J Neurosci. 2007 Aug 22;27(34):9220-32
pubmed: 17715357
J Biol Chem. 2008 Aug 22;283(34):23179-88
pubmed: 18562315
J Am Chem Soc. 2013 Feb 27;135(8):2943-6
pubmed: 23398174
J Exp Med. 2012 May 7;209(5):975-86
pubmed: 22508839
Biopolymers. 2018 Aug;109(10):e23117
pubmed: 29603125
Neuroscience. 2011 Feb 23;175:251-61
pubmed: 21145947
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8284-E8293
pubmed: 28900002
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Synapse. 2012 Jul;66(7):573-83
pubmed: 22337286
J Microsc. 2002 Apr;206(Pt 1):54-64
pubmed: 12000563
Biochemistry. 2000 Sep 5;39(35):10619-26
pubmed: 10978144
Neurobiol Dis. 2015 Oct;82:185-199
pubmed: 26093169
J Neuroinflammation. 2018 May 1;15(1):129
pubmed: 29716614
J Neurosci. 2004 Oct 20;24(42):9434-40
pubmed: 15496679
Sci Rep. 2016 Apr 14;6:24526
pubmed: 27075649
Am J Pathol. 2011 Aug;179(2):954-63
pubmed: 21801874
J Neuroinflammation. 2011 May 09;8:44
pubmed: 21554732
Nature. 2015 Jun 18;522(7556):340-4
pubmed: 26061766
Exp Neurobiol. 2014 Dec;23(4):292-313
pubmed: 25548530
Behav Brain Res. 2017 Aug 30;333:150-160
pubmed: 28668282
Glia. 2013 Mar;61(3):349-60
pubmed: 23108585
Neuron. 2003 Feb 20;37(4):583-95
pubmed: 12597857
EMBO J. 2009 Oct 21;28(20):3256-68
pubmed: 19745811
Neurobiol Aging. 2008 Nov;29(11):1690-701
pubmed: 17537546
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20051-6
pubmed: 19892735
Nat Commun. 2014 May 29;5:3827
pubmed: 24871041
Biol Chem. 2016 May;397(5):401-15
pubmed: 26812789
Int J Mol Sci. 2016 Sep 01;17(9):
pubmed: 27598124
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):571-6
pubmed: 10639120
Biochem Biophys Res Commun. 2008 Aug 1;372(3):423-8
pubmed: 18492487
Proc Natl Acad Sci U S A. 2014 May 27;111(21):7671-6
pubmed: 24817693
Glia. 2008 Aug 15;56(11):1215-23
pubmed: 18449945
J Clin Invest. 2011 Feb;121(2):715-25
pubmed: 21245577
Front Mol Neurosci. 2018 Apr 27;11:144
pubmed: 29755317
ACS Chem Biol. 2014 Oct 17;9(10):2309-17
pubmed: 25079908
Brain Res. 2015 Dec 2;1628(Pt B):247-253
pubmed: 26080075
Cells. 2020 Oct 14;9(10):
pubmed: 33066427
Br J Pharmacol. 2018 Aug;175(16):3298-3314
pubmed: 29570770
ACS Chem Biol. 2019 Jul 19;14(7):1593-1600
pubmed: 31074957
J Neural Transm Suppl. 2000;(60):277-90
pubmed: 11205147
Am J Pathol. 1998 Apr;152(4):879-84
pubmed: 9546347
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S200-4
pubmed: 20082990
Exp Neurol. 2016 Dec;286:83-92
pubmed: 27697481
Neuroscience. 2015 Aug 27;302:23-35
pubmed: 25907448
J Neurosci. 2009 Mar 18;29(11):3365-73
pubmed: 19295143
J Mol Biol. 2002 Oct 4;322(5):1089-102
pubmed: 12367530
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Front Cell Neurosci. 2018 Aug 06;12:247
pubmed: 30127724
Brain. 2009 Feb;132(Pt 2):288-95
pubmed: 18567623
Science. 2017 Dec 15;358(6369):1440-1443
pubmed: 29242346
FASEB J. 2005 Apr;19(6):533-42
pubmed: 15791003
J Biol Chem. 2019 Jul 5;294(27):10392-10406
pubmed: 31142553
Neuron. 2011 Oct 6;72(1):57-71
pubmed: 21982369
J Biol Chem. 2000 Mar 24;275(12):8812-6
pubmed: 10722726
J Biol Chem. 2006 Oct 6;281(40):29739-52
pubmed: 16847063
Neurobiol Dis. 2006 Feb;21(2):404-12
pubmed: 16182554